Ausgabe 3/2008
Inhalt (9 Artikel)
Molecular predictors of response to EGFR antibodies in colorectal cancer
Astrid Lièvre, Pierre Laurent-Puig
Sequential chemotherapy for advanced colorectal cancer: Should we ever start with a single cytotoxic agent?
Matthew T. Seymour, Cornelis J. A. Punt
Should bevacizumab be continued beyond progression in colorectal cancer?
Axel Grothey, Dirk Arnold, Lee M. Ellis
The future of TNM staging in rectal cancer: The era of neoadjuvant therapy
Iris D. Nagtegaal, Corrie A. M. Marijnen
Neoadjuvant or adjuvant therapy for patients with resectable liver metastases
Michael A. Choti, Timothy M. Pawlik
Irinotecan versus oxaliplatin for adjuvant colon cancer therapy: Why do the results differ?
Sujatha Nallapareddy, S. Gail Eckhardt, Wells Messersmith